4.5 Article

Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 73, Issue 9, Pages 1731-1737

Publisher

WILEY
DOI: 10.1002/art.41732

Keywords

-

Categories

Funding

  1. NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [K24-AR-063120, R01-AR-07047]

Ask authors/readers for more resources

The DETECT algorithm shows high sensitivity and negative predictive value in diagnosing PAH, especially among individuals with DLco >= 60%.
Objective. Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc). This study was undertaken to assess predictive accuracies of the DETECT algorithm and the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines in SSc patients who underwent right-sided heart catheterization (RHC) for pulmonary hypertension (PH) evaluation. Methods. Patients with SSc who had diagnostic RHC, had no PH or had PAH, and had available data on variables to allow application of the DETECT and 2015 ESC/ERS guidelines were included for analysis. PH classification was based on hemodynamics using the 2018 revised criteria and extent of lung fibrosis shown on high-resolution computed tomography. Sensitivity and predictive accuracies of the DETECT algorithm and 2015 ESC/ERS guidelines were calculated, including analysis of subjects with a diffusing capacity for carbon monoxide (DLco) of >= 60% predicted. Results. Sixty-eight patients with SSc had RHC, of whom 58 had no PH and 10 had PAH. The mean age was 60.0 years, and 58.8% had limited cutaneous SSc. The DETECT algorithm had a sensitivity of 1.00 (95% confidence interval [95% CI] 0.69-1.00) and a negative predictive value (NPV) of 1.00 (95% CI 0.80-1.00), whereas the 2015 ESC/ERS guidelines had a sensitivity of 0.80 (95% CI 0.44-0.97) and an NPV of 0.94 (95% CI 0.81-0.99). In patients with a DLco of >= 60% (n = 27), the DETECT algorithm had a sensitivity of 1.00 (95% CI 0.29-1.00) and an NPV of 1.00 (95% CI 0.59-1.00), whereas the 2015 ESC/ERS guidelines had a sensitivity of 0.67 (95% CI 0.09-0.99) and an NPV of 0.94 (95% CI 0.71-1.00). Conclusion. The DETECT algorithm has high sensitivity and NPV for diagnosis of PAH, including among individuals with a DLco of >= 60%.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension

Nicole M. Bhave, Scott H. Visovatti, Brian Kulick, Theodore J. Kolias, Vallerie V. McLaughlin

INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2017)

Letter Respiratory System

Physical activity and quality of life in patients with pulmonary hypertension

Thomas M. Cascino, Vallerie V. McLaughlin, Caroline R. Richardson, Nilofar Behbahani-Nejad, Victor M. Moles, Scott H. Visovatti, Elizabeth A. Jackson

EUROPEAN RESPIRATORY JOURNAL (2019)

Article Rheumatology

Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis

Amber Young, Dharshan Vummidi, Scott Visovatti, Kate Homer, Holly Wilhalme, Eric S. White, Kevin Flaherty, Vallerie McLaughlin, Dinesh Khanna

ARTHRITIS & RHEUMATOLOGY (2019)

Article Medicine, Research & Experimental

ENTPD-1 disrupts inflammasome IL-1β-driven venous thrombosis

Vinita Yadav, Liguo Chi, Raymond Zhao, Benjamin E. Tourdot, Srilakshmi Yalavarthi, Benjamin N. Jacobs, Alison Banka, Hui Liao, Sharon Koonse, Anuli C. Anyanwu, Scott H. Visovatti, Michael A. Holinstat, J. Michelle Kahlenberg, Jason S. Knight, David J. Pinsky, Yogendra Kanthi

JOURNAL OF CLINICAL INVESTIGATION (2019)

Article Respiratory System

Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis

Sara Jaafar, Scott Visovatti, Amber Young, Suiyuan Huang, Paul Cronin, Dharshan Vummidi, Vallerie McLaughlin, Dinesh Khanna

EUROPEAN RESPIRATORY JOURNAL (2019)

Article Rheumatology

Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis

Vivek Nagaraja, Marco Matucci-Cerinic, Daniel E. Furst, Masataka Kuwana, Yannick Allanore, Christopher P. Denton, Ganesh Raghu, Vallerie Mclaughlin, Panduranga S. Rao, James R. Seibold, John D. Pauling, Michael L. Whitfield, Dinesh Khanna

ARTHRITIS & RHEUMATOLOGY (2020)

Article Medicine, Research & Experimental

Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial

Dinesh Khanna, Cristina Padilla, Lam C. Tsoi, Vivek Nagaraja, Puja P. Khanna, Tracy Tabib, J. Michelle Kahlenberg, Amber Young, Suiyuan Huang, Johann E. Gudjonsson, David A. Fox, Robert Lafyatis

Summary: This study found that the Janus kinase inhibitor tofacitinib was safe and well-tolerated in patients with early diffuse cutaneous systemic sclerosis (SSc). Gene expression analysis showed that tofacitinib inhibited inflammation in specific cell populations of SSc patients, indicating potential therapeutic effects. These findings are important for understanding the pathogenesis of SSc and developing new treatment strategies.

JCI INSIGHT (2022)

Article Cardiac & Cardiovascular Systems

Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis

Christopher Lewis, Ryan Sanderson, Nektarios Vasilottos, Alexander Zheutlin, Scott Visovatti

HEART FAILURE CLINICS (2023)

Review Immunology

Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease

Ashima Makol, Vivek Nagaraja, Chiemezie Amadi, Janelle Vu Pugashetti, Elaine Caoili, Dinesh Khanna

Summary: Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (SSc). Early recognition and intervention are critical with the FDA approval of two medications and a pipeline of novel therapeutics in trials. There is a need to develop and validate more innovative screening modalities to improve the diagnosis of SSc-ILD.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Barriers to physical activity in patients with pulmonary hypertension

Thomas M. Cascino, Vallerie V. McLaughlin, Caroline R. Richardson, Nilofar Behbahani-Nejad, Victor M. Moles, Scott H. Visovatti, Elizabeth A. Jackson

PULMONARY CIRCULATION (2019)

Article Biochemistry & Molecular Biology

Nanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting

Rahul Rattan, Somnath Bhattacharjee, Hong Zong, Corban Swain, Muneeb A. Siddiqui, Scott H. Visovatti, Yogendra Kanthi, Sajani Desai, David J. Pinsky, Sascha N. Goonewardena

BIOORGANIC & MEDICINAL CHEMISTRY (2017)

Article Cardiac & Cardiovascular Systems

Usefulness of Echocardiography/Doppler to Reliably Predict Elevated Left Ventricular End-Diastolic Pressure in Patients With Pulmonary Hypertension

David M. Cameron, Vallerie V. McLaughlin, Melvyn Rubenfire, Scott Visovatti, David S. Bach

AMERICAN JOURNAL OF CARDIOLOGY (2017)

Article Medicine, Research & Experimental

Ectonucleotidase CD39-driven control of postinfarction myocardial repair and rupture

Nadia R. Sutton, Takanori Hayasaki, Matthew C. Hyman, Anuli C. Anyanwu, Hui Liao, Danica Petrovic-Djergovic, Linda Badri, Amy E. Baek, Natalie Walker, Keigo Fukase, Yogendra Kanthi, Scott H. Visovatti, Ellen L. Horste, Jessica J. Ray, Sascha N. Goonewardena, David J. Pinsky

JCI INSIGHT (2017)

No Data Available